A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy

被引：0
|
作者：
Tianhong Yang
Lei Peng
Jia Qiu
Xingjin He
Dake Zhang
Renbo Wu
Jianbo Liu
Xiangsong Zhang
Zhihao Zha
机构：
[1] The First Affiliated Hospital of Sun Yat-Sen University,Department of Nuclear Medicine
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2023年 / 50卷
关键词：
Silicon-fluoride-acceptor; FAP inhibitor; Radiohybrid; Theranostics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2331 / 2341
页数：10
相关论文
共 27 条
  • [1] A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy
    Yang, Tianhong
    Peng, Lei
    Qiu, Jia
    He, Xingjin
    Zhang, Dake
    Wu, Renbo
    Liu, Jianbo
    Zhang, Xiangsong
    Zha, Zhihao
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (08) : 2331 - 2341
  • [2] Fluorine-18 labeled fibroblast activation protein alpha targeting ligand: In vitro and in vivo studies
    Roy, Jyoti
    Jagoda, Elaine
    Basuli, Falguni
    Olkowski, Colleen
    Zhang, Xiang
    Wong, Karen
    Woodroofe, Carolyn
    Swenson, Rolf
    Choyke, Peter
    Lin, Frank
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
  • [3] PRELIMINARY INVESTIGATION OF A GALLIUM-68, COPPER-64 AND LUTETIUM-177 LABELED PSMA TARGETING LIGAND FOR IMAGING AND RADIONUCLIDE THERAPY OF PROSTATE CANCER
    Weineisen, M.
    Roselt, P.
    Cullinane, C.
    O'Keefe, G.
    Rigopoulos, A.
    Hicks, R.
    Wester, H. J.
    INTERNAL MEDICINE JOURNAL, 2015, 45 : 4 - 5
  • [4] Safety of Fibroblast Activation Protein-Targeted Radionuclide Therapy by a Low-Dose Dosimetric Approach Using 177Lu-FAPI04
    Kuyumcu, Serkan
    Kovan, Bilal
    Sanli, Yasemin
    Buyukkaya, Fikret
    Simsek, Duygu Has
    Ozkan, Zeynep Gozde
    Isik, Emine Goknur
    Ekenel, Meltem
    Turkmen, Cuneyt
    CLINICAL NUCLEAR MEDICINE, 2021, 46 (08) : 641 - 646
  • [5] Bacterial Endotoxin and Sterility Testing of Active Pharmacological Ingredients used in the production of different Fluorine-18, Gallium-68 and Lutetium-177 labeled Radiopharmaceuticals
    Mitra, A.
    Lad, S.
    Kulkarni, S.
    Rajan, M. G. R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S487 - S487
  • [6] Fibroblast activation protein (FAP)-targeted radionuclide therapy: which ligand is the best?
    Rubel Chakravarty
    Wenyu Song
    Sudipta Chakraborty
    Weibo Cai
    European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 2935 - 2939
  • [7] Fibroblast activation protein (FAP)-targeted radionuclide therapy: which ligand is the best?
    Chakravarty, Rubel
    Song, Wenyu
    Chakraborty, Sudipta
    Cai, Weibo
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (10) : 2935 - 2939
  • [8] Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies
    Prive, Bastiaan M. M.
    Boussihmad, Mohamed A. A.
    Timmermans, Bart
    van Gemert, Willemijn A. A.
    Peters, Steffie M. B.
    Derks, Yvonne H. W.
    van Lith, Sanne A. M.
    Mehra, Niven
    Nagarajah, James
    Heskamp, Sandra
    Westdorp, Harm
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (07) : 1906 - 1918
  • [9] Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies
    Bastiaan M. Privé
    Mohamed A. Boussihmad
    Bart Timmermans
    Willemijn A. van Gemert
    Steffie M. B. Peters
    Yvonne H. W. Derks
    Sanne A. M. van Lith
    Niven Mehra
    James Nagarajah
    Sandra Heskamp
    Harm Westdorp
    European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 1906 - 1918
  • [10] Fibroblast activation protein-targeted radionuclide therapy of solid tumors using [177Lu]Lu-DOTAGA-Glu-(FAPi)2: biodistribution and dosimetry
    Kurth, Jens
    Krause, Bernd
    Lanzafame, Helena
    Joksch, Markus
    Fendler, Wolfgang
    Herrmann, Ken
    Roesch, Frank
    Heuschkel, Martin
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
123